While some have postulated that BAT may reverse transdifferentiation of prostate adenocarcinoma to neuroendocrine prostate cancer, which can occur as a mechanism of resistance to AR-axis inhibitors (37), we did not assess this possibility in the current study. Here, AR is linked to prostate adenocarcinoma.